bluebird bio, Inc. (NASDAQ:BLUE) had its price objective boosted by BMO Capital Markets from $134.00 to $162.00 in a report issued on Monday, October 30th, MarketBeat Ratings reports. BMO Capital Markets currently has a buy rating on the biotechnology company’s stock.
A number of other research firms also recently commented on BLUE. Jefferies Group LLC restated a buy rating and set a $88.00 price objective on shares of bluebird bio in a report on Friday, August 11th. Zacks Investment Research raised shares of bluebird bio from a hold rating to a buy rating and set a $118.00 price target on the stock in a research report on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) reiterated a buy rating and set a $186.00 price objective on shares of bluebird bio in a research note on Friday, October 6th. Maxim Group reiterated a buy rating and set a $170.00 price objective (up previously from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Finally, Morgan Stanley raised their price target on shares of bluebird bio from $103.00 to $105.00 and gave the company an equal weight rating in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. bluebird bio has a consensus rating of Buy and an average price target of $131.05.
bluebird bio (NASDAQ BLUE) traded up $2.80 on Monday, hitting $154.55. The stock had a trading volume of 553,100 shares, compared to its average volume of 843,318. bluebird bio has a twelve month low of $55.65 and a twelve month high of $164.80.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same period in the prior year, the firm posted ($2.07) EPS. bluebird bio’s revenue for the quarter was up 397.4% compared to the same quarter last year. research analysts forecast that bluebird bio will post -6.68 EPS for the current fiscal year.
WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://weekherald.com/2017/11/14/bluebird-bio-inc-blue-pt-raised-to-162-00.html.
In related news, Director Daniel Lynch sold 500 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the transaction, the director now owns 3,300 shares in the company, valued at $396,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey T. Walsh sold 9,900 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $149.58, for a total transaction of $1,480,842.00. Following the transaction, the insider now owns 28,798 shares of the company’s stock, valued at approximately $4,307,604.84. The disclosure for this sale can be found here. Insiders sold 193,168 shares of company stock valued at $25,558,003 in the last quarter. Corporate insiders own 3.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of BLUE. BlackRock Inc. raised its position in bluebird bio by 44,948.0% during the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock worth $289,259,000 after acquiring an additional 3,175,124 shares in the last quarter. FMR LLC grew its stake in shares of bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after acquiring an additional 587,236 shares in the last quarter. Capital Research Global Investors grew its stake in shares of bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after acquiring an additional 493,072 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of bluebird bio by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after purchasing an additional 343,856 shares in the last quarter. Finally, Eagle Asset Management Inc. acquired a new stake in shares of bluebird bio in the 3rd quarter valued at approximately $29,539,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.